Results 211 to 220 of about 28,620 (235)
Some of the next articles are maybe not open access.
Influence of Azimilide on CYP2C19 Mediated Metabolism
Clinical Pharmacology & Therapeutics, 2003Clinical Pharmacology & Therapeutics (2003) 73, P32–P32; doi:
Mohamed, El Mouelhi +4 more
openaire +2 more sources
Journal of clinical pharmacy and therapeutics, 2011
CYP2C19 is a drug-metabolizing enzyme showing various genetic polymorphisms that may cause marked interindividual and interethnic variability in the disposition of its substrates. We assessed CYP2C19 genetic polymorphisms in a Korean population using a newly developed multiplex pyrosequencing method.A multiplex pyrosequencing method to simultaneously ...
K-A, Kim, W-K, Song, K-R, Kim, J-Y, Park
openaire +1 more source
CYP2C19 is a drug-metabolizing enzyme showing various genetic polymorphisms that may cause marked interindividual and interethnic variability in the disposition of its substrates. We assessed CYP2C19 genetic polymorphisms in a Korean population using a newly developed multiplex pyrosequencing method.A multiplex pyrosequencing method to simultaneously ...
K-A, Kim, W-K, Song, K-R, Kim, J-Y, Park
openaire +1 more source
CYP2C19 genetic mutations in North Indians
Clinical Pharmacology & Therapeutics, 2000To identify defective alleles of CYP2C19 (CYP2C19*2 and *3) in North Indians.One hundred extensive metabolizers and 21 poor metabolizers of omeprazole were genotyped with respect to CYP2C19*2 and *3 alleles with polymerase chain reaction-based diagnostic tests.Fifty-two extensive metabolizers and six poor metabolizers were homozygous with the CYP2C19*1/
J K, Lamba, R K, Dhiman, K K, Kohli
openaire +2 more sources
[Genotyping of CYP2D6 and CYP2C19].
Casopis lekaru ceskych, 2008Polymorphisms in drug metabolizing enzymes are considered as a major factor influencing the incidence of adverse drug reactions or failure of pharmacotherapy. Our aim was to compare the distribution of functional polymorphisms in the genes CYP2D6 and CYP2C19 between healthy control group and of patients reffered to our department due to adverse drug ...
O, Slanar +6 more
openaire +1 more source
The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway
The Journal of Clinical Pharmacology, 2016AbstractThe major metabolic pathway of clopidogrel is conversion to carboxylic acid by an esterase (CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the structure of the active metabolite; however, there are differing views about the mechanism of its formation.
openaire +2 more sources
CYP2C19*2 and CYP2C19*3 allelomorphism in Turkish population
International Journal of Cardiology, 2017openaire +3 more sources